Active Biotech says first amended-protocol cohort clears safety review in HOVON 172 MF tasquinimod trial
Bitget2026/10/13 13:03- Active Biotech reported the first three-patient safety cohort completed a six-week evaluation in the HOVON 172 MF tasquinimod study.
- Results have been presented now as an interim safety update from patients enrolled under an amended dosing protocol.
- One serious adverse event met dose-limiting toxicity criteria, resolved with medical management, and the patient stayed on treatment.
- No additional dose-limiting toxicities were seen; all three patients remained on therapy, supporting continued development in myelofibrosis.
- Enrollment will expand to three more patients; the recommended Phase II dose regimen is expected once that safety check is completed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tesla (TSLA.US) drops over 10% in a week, but ARK keeps buying! Cathie Wood: This is the moment we've been waiting for
Despite the recent volatility in Tesla's stock price, ARK Invest founder Cathie Wood, known as the "Goddess of Wall Street," remains optimistic about the company.
U.S. stock futures fluctuate by $650 billions due to news related to Jensen Huang
Nikkei Average Index gains expand to 2.78%
Surprise! Japan intervened in the forex market three times this summer, selling a record 154 trillion yen in three days
Japan has confirmed that it intervened in the foreign exchange market three times this summer, buying yen to support the exchange rate, corroborating earlier market reports. This included the first joint intervention with the United States to support the yen in nearly thirty years.
Crypto prices
More
